Business Context and Reporting Period
Coherus BioSciences, Inc. filed this Form 8-K on March 9, 2018, to report a significant legal development regarding its intellectual property strategy. The company is a biopharmaceutical firm focused on developing biosimilars, including a version of etanercept.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the denial of two Inter Partes Review (IPR) petitions by the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. The petitions, filed by Coherus, targeted U.S. Patents 8,163,522 (the '522 patent) and 8,063,182 (the '182 patent), both controlled by Amgen Inc. These patents cover the method of making etanercept and the etanercept protein itself, which are relevant to Coherus's biosimilar development.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future outlook. The denial of the IPRs represents a contingency and risk, as it maintains the validity of Amgen's patents, potentially complicating Coherus's path to commercializing its etanercept biosimilar without facing patent infringement claims.
Investor Verification Checklist
- Verify the specific legal grounds for the PTAB's denial of the IPR petitions.
- Assess the impact of the upheld Amgen patents on Coherus's commercialization timeline for its etanercept biosimilar.
- Review Coherus's subsequent legal strategy or potential appeals regarding the '522 and '182 patents.
- Check for any updated financial guidance in subsequent filings that may reflect the cost or delay associated with this legal outcome.